Reported about 12 hours ago
Johnson & Johnson faced a stock drop over 3% due to risks from a talc lawsuit and generic competition for Stelara, despite exceeding earnings expectations. CFO Joe Wolk considers these challenges manageable, projecting growth amid market headwinds, particularly from generic rivals and new Medicare pricing. The company is also expanding its neuroscience portfolio, notably with a $14.6 billion acquisition to strengthen its position in the Alzheimer's market.
Source: YAHOO